Thymosin Alpha-1 the science.

Thymosin Alpha-1 (Tα1) is a small, naturally occurring peptide first characterized from thymic tissue, where peptides of this family are associated with maturation and regulation of the immune system. It is produced by cleavage from the larger precursor protein prothymosin α, and is synthesized for research and, in some markets, pharmaceutical use.

It has been studied as an immune modulator — a molecule that adjusts immune activity rather than simply suppressing or stimulating it. In some countries it is marketed as the drug Zadaxin; in the United States it remains investigational and is not FDA-approved.

Thymosin Alpha-1 research centers on immune signaling:

• T-cell modulation — effects on the maturation, differentiation, and function of T lymphocytes.
• Innate-immune & receptor signaling — interactions studied in the context of toll-like-receptor pathways and dendritic-cell function.
• Immune-balance framing — research examines its role in restoring or modulating immune responses under stress, infection, or immunosuppression.

Thymosin Alpha-1 has both extensive preclinical work and published human clinical trials:

• Severe sepsis trial (ETASS, 2013). A multicenter, randomized, controlled trial (published in Critical Care) evaluated thymosin alpha 1 as an immunomodulatory treatment in patients with severe sepsis.
• Systematic reviews. Reviews and meta-analyses have summarized randomized-trial evidence on thymosin alpha 1 as an immunomodulatory treatment for sepsis.
• Other infection & immune contexts. The peptide has a long clinical research history in viral-hepatitis and immune-support contexts in countries where it is marketed.

This material is supplied for research use only. Approval status differs by country, and no U.S.-approved indication, dosing, or therapeutic claim applies here.

Thymosin Alpha-1 has an extensive evidence base including human clinical trials, and is an approved medicine in some countries (as Zadaxin). It is not FDA-approved in the United States, and no U.S.-approved indication, dosing, or therapeutic claim applies. Thymosin Alpha-1 is supplied strictly as a research material for laboratory investigation.